Silo Pharma shares surge 20.09% intraday after announcing $1M share repurchase program to boost investor confidence.

Silo Pharma (SILO) surged 20.09% intraday following the announcement of a $1 million share repurchase program, signaling management’s confidence in its valuation and aiming to reduce shares outstanding, thereby boosting earnings per share and investor confidence. The buyback, first disclosed in pre-market trading, was widely reported across multiple outlets, with analyses noting its potential to enhance stock price momentum amid ongoing R&D progress for SPC-15, a PTSD treatment candidate. While the company reported a wider net loss in Q3, the repurchase initiative aligns with its strategy to optimize capital structure and support future growth in biopharmaceutical innovation. The intraday rally reflects strong short-term optimism, though technical indicators suggest the move remains speculative, with trading volume below 60-day averages.